Method for synthesizing...

Details Method for synthesizing... Method for synthesizing...

2005-05-24

2005-05-24

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S027140, C536S028400, C544S317000, C544S320000, C549S476000

Reexamination Certificate

active

06897302

ABSTRACT:
The invention provides a method of synthesizing β-L-5-fluoro-2′,3′-dideoxy-2′,3′-didehydrocytidine (β-L-FD4C). The method allows for large-scale production of β-L-FD4C in an efficient, cost-effective, and environmentally sound manner.

REFERENCES:
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5561120 (1996-10-01), Lin et al.
patent: 5627160 (1997-05-01), Lin et al.
patent: 5631239 (1997-05-01), Lin et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5756478 (1998-05-01), Cheng et al.
patent: 5830881 (1998-11-01), Lin et al.
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5905070 (1999-05-01), Schinazi et al.
patent: 6005097 (1999-12-01), Chen et al.
patent: 6280940 (2001-08-01), Potts et al.
patent: 6306899 (2001-10-01), Cheng et al.
patent: 20020098202 (2002-07-01), Wimmer et al.
patent: 20020111313 (2002-08-01), Campbell et al.
patent: 20020147160 (2002-10-01), Bhat et al.
patent: 9214743 (1992-09-01), None
patent: 9427616 (1994-12-01), None
patent: 9747635 (1997-12-01), None
Gulakowski, et al., “A Semiautomatic Multiparameter Approach for Anti-HIV Drug Screening,”Journal of Virological Methods, vol. 33, pp. 87-100 (1991).
Elmore, et al., “The Human Epithelial Cell Cytotoxicity Assay for Determining Tissue Specific Toxicity,”Methods in Cell Science, vol. 22, pp. 17-24, (2000).
Elmore, et al., “Comparative Tissue-Specific Toxicities of 20 Caner Preventive Agents Using Cultured Cells From 8 Different Normal Human Epithelia,” in Vivo &Molecular Toxicology, vol. 14(3), pp. 191-207.
Lohmann, et al., “Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line,”Science, vol. 285, pp. 110-113 (1999).
Mitsuya, et al., “3′-Azido-3′-dexoythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in Vitro”Proc. Natl. Acad Sci. USA, vol. 82, pp. 7096-7100 (1985).
Mitsuya, et al., “Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides”Proc Natl. Acad. Sci USA, vol. 83, pp. 1911-1915 (1986).
Mansuri, et al., “1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosy1) thymine. A Highly Potent and Selective Anti-HIV Agent”J. Med. Chem., vol. 32, pp. 461-466 (1989).
Jeong, et al., “Asymmetric Synthesis and Biological Evaluation of β-L-(2E,5S)- and α-L-(2R,5R)-1,3-Oxathiolane-Pyrimidine and -Purine Nucleosides as Potential Anti-HIV Agents”J. Med. Chem., vol. 36(2), pp. 181-195 (1993).
Lin, et al., “Rapid Communications: Antiviral Activity of 2′,3′-Dideoxy- β-L-5-Fluorocytidine (β-L-FddC) and 2′,3′-Dideoxy-β-L-Cytidine (β-L-ddC) Against Hepatitis B Virus and Human Immunodeficiency Virus Type 1 in Vitro”Biochem. Pharmacol., vol. 47(2) pp. 171-174 (1994).
Lin, et al., “Design and Synthesis of 2′,3′-Dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-Dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro”J. Med. Chem., vol. 39(9), pp. 1757-1759 (1996).

Affiliated with

Also associated with

Rating

Method for synthesizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for synthesizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for synthesizing... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3431185